Andrew S. Plump - 10 Aug 2026 Form 4 Insider Report for TAKEDA PHARMACEUTICAL CO LTD (TAK)

Reporting relationship: President, R&D, Director
Issuer ticker: TAK
Reported as of: 10 Aug 2026
Net transaction value: -$2,828,220
SEC form: 4
Accepted by SEC: 12 Aug 2026, 21:50:30 UTC
Prior SEC filing: 06 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Samuel Ntonme, by power of attorney, for Andrew S Plump

Key filing fact

Andrew S. Plump filed Form 4 for TAKEDA PHARMACEUTICAL CO LTD (TAK) on 12 Aug 2026.

Key facts

This page summarizes Andrew S. Plump's Form 4 filing for TAKEDA PHARMACEUTICAL CO LTD (TAK).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 12 Aug 2026, 21:50.

Change

Previous filing in this sequence was filed on 06 Jul 2026.
Current net transaction value: -$2,828,220.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001977689 Primary reporting owner

Plump Andrew Stewart

Relationship: President, R&D, Director
Address: 300 MASSACHUSETTS AVE., CAMBRIDGE
Signature: /s/ Samuel Ntonme, by power of attorney, for Andrew S Plump
Signature date: 12 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TAK transaction

American Depositary Shares

Sale

Transaction value: $2,828,220
Shares: -165,393
Change %: -18%
Price: $17.10
Shares after: 766,569
Date: 10 Aug 2026
Ownership: Direct
Footnotes: F1, F2

TAK holding

American Depositary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 281,307
Date: 10 Aug 2026
Ownership: By Trust

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents a mandatory sale to cover taxes associated with the vesting of equity awards held by the Reporting Person.

Footnote F2

The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.